ExSight Ventures — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration.
BiotechMedical DevicesBerkeley, US
Wesley Jackson(President, Chief Scientific Officer & Member of the Board)inGregory D. Kunst(Chief Executive Officer)Carole H Bellis(Executive Officer)Kevin E Healy(Director)Jackson M Wesley(Executive Officer, Director)
BoardDrew Lanza(Director)in
Co-investorsAngel Physicians FundBerkeley CatalystFirst Spark Ventures, LlcPandect BioventuresExSight
Vana is an open data infrastructure platform that enables individuals to control and manage the data they generate, with the ability to choose how it is used by AI systems.
AI & Machine LearningData & Infrastructure
Art Abal(Founder)
Co-investorsAbstract VenturesAlphaLab CapitalCaladanEarl Grey CapitalParadigmSCB 10X+7 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.